The publisher regrets that Figure 2 was incomplete in the published article.
The full Figure 2 is given in the following context.
The publisher would like to apologise for any inconvenience caused.
Published online: March 13, 2021
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Identification of nephronectin as a new target for IGF1 actionEuropean Journal of CancerVol. 141
- PreviewThe growth hormone (GH)-insulin-like growth factor-1 (IGF1) endocrine axis has a key role in normal growth and development. Laron syndrome (LS) is a type of dwarfism that results from mutation of the GH receptor, leading to congenital IGF1 deficiency. Epidemiological studies have shown that LS patients are protected from cancer. Genome-wide profiling led to the identification of a series of metabolic genes whose differential expression in LS might be linked to cancer protection. Nephronectin (NPNT) is an intracellular and secreted extracellular matrix protein with important roles in kidney development.